Shanghai IMINOVA Biotechnology Co., Ltd. has recently unveiled the successful closure of its Series A funding round, amassing RMB 250 million. This pivotal financing was spearheaded by Vivo Capital, with additional participation from Gaoma Yuanhang. Notably, existing stakeholders Xicheng Jinrui and Taiyu Investment also substantially ramped up their investments. The newly acquired funds will be predominantly channeled towards advancing the research and development of the gene-edited animal platform, facilitating the commercialization of the fully human antibody rabbit platform, and constructing an AI-driven antibody drug screening platform.

Since its inception in 2020, IMINOVA has been dedicated to harnessing gene-editing technology to pioneer the next generation of antibody discovery platforms. The company's proprietary MASIRT® technology has achieved three significant milestones, successfully establishing a multi-species fully human antibody animal platform and concurrently propelling the development of the MabAI® AI antibody discovery platform. Presently, IMINOVA boasts a comprehensive collaboration framework, with its technology having undergone rigorous validation by esteemed international partners.

Founder Zhang Jiwei emphasized that the company will leverage its core technologies to expedite platform development and pipeline layout (here, "pipeline layout" retains its original Chinese pinyin meaning, though it could be translated as "pipeline deployment" in English contexts). Investors, including Vivo Capital, have expressed unwavering confidence in IMINOVA's technological prowess and platforms, eagerly anticipating the opportunity to jointly foster its future expansion and success.